Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6874281 dose-escalation study as monotherapy or with trastuzumab/cetuximab
NL-OMON46970Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of simlukafusp alfa in Nonhematologic neoplasms, breast cancer and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Roche. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and infusion-related reactions and 14 more. Started Dec 2015; status: active, not recruiting.
02
Drugs
simlukafusp alfa
03
Conditions
Nonhematologic neoplasmsbreast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON46970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46970.